Orthopedic biologics supplier serving Salt Lake City, UT

How orthopedic groups vet a biologics distributor

Practices that bring in tissue or exosome products from an outside supplier generally start by requesting the same records a quality or compliance reviewer would ask for: a certificate of analysis for the lot in question, a donor eligibility summary, and a lot release record showing the product cleared internal testing before shipment. Group practices and surgery centers often route this request through a practice manager or compliance lead rather than an individual physician.

Precision Biologics provides these records to verified accounts on request and can walk a practice's compliance contact through what each document covers.

NPI-verified accounts

Every account is tied to a National Provider Identifier. This mirrors the same NPPES registry referenced above, which is why a practice's own NPI record is the starting point for setup rather than a sales form. Ordering access is limited to licensed professionals, and a practice can designate who on staff is authorized to place orders once the account is verified.

Cold chain and receiving in the Mountain West

Cryopreserved Wharton's jelly formats are stored at -80 degrees C and shipped overnight on dry ice in validated containers; this logistics model applies the same way to a clinic in Salt Lake City as anywhere else in the country, and a front desk or receiving staff member should know to move the shipment to appropriate storage immediately on arrival.

For practices that prefer not to manage cryogenic storage, the lyophilized Wharton's jelly format is shelf-stable and reconstituted per the insert included with the lot, which can simplify receiving for a smaller clinic or an ambulatory surgery center.

Confirming regulatory posture

Precision Biologics does not advise on clinical use, dosing, or procedures. Whether a given intended use of a Wharton's jelly product fits within the homologous-use and minimal-manipulation criteria in 21 CFR 1271.10 is a determination for the practice and its own counsel, and exosome products are not approved by the FDA and are generally regulated as biologic drugs. Orthopedic groups in Utah should verify their own regulatory posture with the Utah medical board and legal counsel before adding any new product category to their intake process.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.